ArticleRespiratory research2021

Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.

Theodoros Karampitsakos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.